Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 43

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 43
---
 Exclusive License Agreement, dated March 22, 2022, with The Regents
of the University of California.

In October 2024 and December
2024, we entered into a strategic development services contract with Lantheus to advance clinical development of innovative radiopharmaceuticals
in Australia. Under the contract, Radiopharm will lead the clinical development efforts in Australia while Lantheus covers all the clinical
development costs associated with the program. Radiopharm will also receive up to US$2 million as one-off milestone payments upon achieving
key clinical development objectives.

In November 2024, our ADSs,
each representing 300 ordinary shares, listed on Nasdaq under the symbol “ RADX”.

In January 2025, we entered
into a Share Subscription Agreement with Lantheus Holdings. Under the terms of the agreement, Lantheus Holdings purchased 133,000,000
ordinary shares for US$5.0 million at A$0.06 per share.

Our registered office is located
at Suite 1, Level 3, 62 Lygon Street, Carlton, Victoria 3053, Australia, and our telephone number is +61 3 9824 5254. Our address on the
Internet is www. radiopharmtheranostics. com. The information on, or accessible through, our website is not part of this Annual Report on
Form 20-F. We have included our website address in this Annual Report on Form 20-F solely as an inactive textual reference. All information
we file with the U. S. Securities and Exchange Commission (“ SEC”) is available through the SEC’s Electronic Data Gathering,
Analysis and Retrieval system, which may be accessed through the SEC’s website at www. sec. gov.

B. Business Overview

Strategy

We are a research and development
company that aims to develop and commercialize platforms of radiopharmaceutical products for both therapeutic and diagnostic applications
in precision oncology.

We develop targeted and scientifically
validated radiopharmaceutical technologies that are in both pre-clinical and clinical stages of development. These technologies span all
size molecules comprising peptides, small molecules and antibodies attached to medical quality radioisotopes. We are pursuing registration
and marketing approval for each product and therapy under development in the United States, the European Union, the United Kingdom, China,
Japan, Australia and Canada.

To achieve our goals, we intend to:

  Focus on tumor types that can be considered radiosensitive. There are